Skip to content

Neuropsychological Impact of Hospitalization on Intubated, Ventilated and Sedated ICU Patients

Neuropsychological Impact of Hospitalization on Intubated, Ventilated and Sedated ICU Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01838798
Acronym
NeuroPsy Réa
Enrollment
125
Registered
2013-04-24
Start date
2013-11-30
Completion date
2016-10-31
Last updated
2025-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression, Stress Disorders, Post-Traumatic

Keywords

cognitive disorders, quality of life, Intensive care

Brief summary

This is a prospective, single-center, pilot, cohort study. The first phase of this study is observational and the usual care of patients is maintained during the ICU stay, except for an interview with a psychologist preceding patient discharge. A phone interview at 2 months and a visit with a psychologist at four months after ICU discharge are specific to the study. The main objective of this study is to make a first estimate of the percentage of patients (CI = +- 10%) with cognitive impairment at four months after ICU discharge. The presence / absence of cognitive impairment will be determined by the D2 test.

Detailed description

The secondary objectives of this study are: A. To study the potential links between cognitive impairment and quality of life 4 months after discharge from the Intensive Care Unit. B. To study the associations between variables measured during hospitalization. Is there clustering among certain symptoms during hospitalization? C. To study the associations between variables measured at two and four months after ICU discharge. Is there clustering among these symptoms? D. To study potential risk factors for cognitive problems at 4 months after ICU discharge. E. If objective C determines the presence of clusters, is the presence / absence of these clusters related to the variables (or clusters of variables) measured during hospitalization? F. To study potential risk factors for poor quality of life at 4 months:

Interventions

Initial consent procedures and baseline data collection.

OTHERClinical interview with a psychologist

Clinical interview with a psychologist. This interview with a psychologist will take place after patient consent procedures, and at least 2 days after discontinuation of sedation, and before leaving the ICU. This interview will include: * An inventory of peritraumatic distress symptoms * A questionnaire on peritraumatic dissociative experiences * An assessment of related, potential impacts * The HADS questionnaire

OTHERTelephone interview 2 months after ICU discharge

At 2 months after leaving the ICU, a psychologist will contact the patient with questions regarding his/her representation of hospitalization. This implies the following: * Questionnaires assessing memories and stressors (Questionnaires ICUMT, and ICU-SEQ * An assessment of psychological trauma * An assessment of potential impacts

Sponsors

Centre Hospitalier Universitaire de Nīmes
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* The patient (or his/her trusted person) must have given his/her informed and signed consent * The patient must be insured or beneficiary of a health insurance plan * The patient is available for a telephone interview at 2 months after ICU discharge, and for a follow-up visit at 4 months after ICU discharge * Patient admitted to the ICU and intubated and ventilated for at least 48 hours

Exclusion criteria

* The patient is currently participating in or has participated in another study (within the past 3 months) that might influence the results of the current study * The patient is under judicial protection, under tutorship or curatorship * The patient refuses to sign the consent * It is impossible to correctly inform the patient * The patient is pregnant, parturient, or breastfeeding * The patient has a contra-indication for a treatment used in this study * Patient admitted to intensive care with sedation started for more than 24 hours * Patient with neurological or psychiatric (cognitive) disorders * Patient admitted for cardiac arrest * Patient admitted for stroke * Patient admitted for cervical trauma \> C6 * Patient presenting with tracheotomy accompanied by long-term mechanical ventilation * Moribund patient or with little hope of survival beyond 48 hours * Patients for whom a limitation or termination of care is considered * McCabe Score = 0 * Knauss Scale = C or D

Design outcomes

Primary

MeasureTime frameDescription
Presence/absence of cognitive impairment4 months after ICU dischargebased on D2 test

Secondary

MeasureTime frame
Duration of sedationexpected average of 48 hours
Duration of ventilationexpected average of 36 hours
Daily average for RASS scaleExpected maximum of 28 days
Daily average for Behaviour pain scaleexpected average of 48 hours
CAM ICU scoreupon awakening (expected average of 48 hours)
Peritraumatic distress inventoryexpected average of 5 days (end of ICU stay)
Questionnaire PDEQ-10expected average of 5 days (end of ICU stay)
Assessment of potential impactsexpected average of 5 days (end of ICU stay)
HADS scoreexpected average of 5 days (end of ICU stay)
ICUMT questionnaire60 +- 3 days after ICU discharge
ICU-SEQ questionnaire60 +- 3 days after ICU discharge
Assessment of psychotramatisme60 +- 3 days after ICU discharge
PCLS scale (DSM IV items)4 months after ICU discharge
IDS-C Questionnaire4 months after ICU discharge
SF-364 months after ICU discharge
Forward span test4 months after ICU discharge
Backwards span test4 months after ICU discharge
Rey 15-word test4 months after ICU discharge
Test D2 (units = n)4 months after ICU discharge
Wisconsin test4 months after ICU discharge
Stroop test4 months after ICU discharge
Verbal fluency test4 months after ICU discharge

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026